A 31-year-old man enrolled in an HIV drug trial receives a CCR5 antagonist. He presents with fever (38.2°C), tachycardia (102 bpm), and fatigue. Recent CD4 count is 450 cells/μL with HIV RNA of 85,000 copies/mL. Physical examination reveals no opportunistic infection signs. He denies antiretroviral medication use prior to enrollment. This CCR5-blocking intervention would most directly impair viral entry into which of the following cell types early in HIV infection?
- A)Erythrocytes
- B)CD4 positive T cells and macrophagesGABARITO
- C)B lymphocytes
- D)Neutrophils and eosinophils
- E)Natural killer cells only
Explicação
HIV binds CD4 and then uses coreceptors for entry. Early in infection, macrophage tropic strains commonly use CCR5, so blocking CCR5 impairs infection of CD4 positive T cells and macrophages. Ver explicação completa e trilha adaptativa →